Tiragolumab
(Anti-human TIGIT mAb, human IgG1-Kappa)
Catalog No.: PC-Ab1006Not For Human Use, Lab Use Only.
The first anti-TIGIT (T-cell immunoglobin and ITIM domain protein) mAb, prevent TIGIT from binding to its ligand, could restore the antitumor response and could complement the activity of anti–PD-L1/PD-1 antibodies. Anti-TIGIT mAb (tiragolumab) has demonstrated promising clinical efficacy in non-small cell lung cancer treatment when combined with an anti-PD-L1 drug (Tecentriq), exhibited remarkable efficacy in PD-L1-positive NSCLC patients in phase II clinical trials..
The first anti-TIGIT (T-cell immunoglobin and ITIM domain protein) mAb, prevent TIGIT from binding to its ligand, could restore the antitumor response and could complement the activity of anti–PD-L1/PD-1 antibodies. Anti-TIGIT mAb (tiragolumab) has demonstrated promising clinical efficacy in non-small cell lung cancer treatment when combined with an anti-PD-L1 drug (Tecentriq), exhibited remarkable efficacy in PD-L1-positive NSCLC patients in phase II clinical trials.
Physicochemical Properties
M.Wt
Formula
Human IgG1-Kappa
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
